生物仿制药-话题@MedSci

#生物仿制药#

69篇内容 | 1165人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1412953, encodeId=95971412953f4, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, objectTitle=Alvotech和STADA与艾伯维解决欧洲专利纠纷，为Humira®的无柠檬酸盐、高浓度生物仿制药HUKYNDRA®(AVT02)上市铺平道路, objectType=article, longId=723787, objectId=0b3be23787cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b3be23787cf, replyNumber=0, likeNumber=33, createdTime=2022-04-09, rootId=0, userName=grace5701, userId=cfb42911806, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b3be23787cf, moduleTitle=Alvotech和STADA与艾伯维解决欧洲专利纠纷，为Humira®的无柠檬酸盐、高浓度生物仿制药HUKYNDRA®(AVT02)上市铺平道路, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b3be23787cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412952, encodeId=588a1412952cd, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, objectTitle=FDA批准Releuko(filgrastim-ayow) ，第三种非格司亭生物仿制药, objectType=article, longId=301203, objectId=bed4301203e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bed4301203e3, replyNumber=0, likeNumber=34, createdTime=2022-03-21, rootId=0, userName=grace5701, userId=cfb42911806, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bed4301203e3, moduleTitle=FDA批准Releuko(filgrastim-ayow) ，第三种非格司亭生物仿制药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bed4301203e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412951, encodeId=7055141295169, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, objectTitle=Alvotech就美国专利和商业秘密纠纷与AbbVie达成和解，Alvotech的拟议Humira®高浓度生物仿制药(AVT02)可在美国销售, objectType=article, longId=300761, objectId=3b82300e6134, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b82300e6134, replyNumber=0, likeNumber=0, createdTime=2022-03-16, rootId=0, userName=grace5701, userId=cfb42911806, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b82300e6134, moduleTitle=Alvotech就美国专利和商业秘密纠纷与AbbVie达成和解，Alvotech的拟议Humira®高浓度生物仿制药(AVT02)可在美国销售, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b82300e6134)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412950, encodeId=5210141295038, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, objectTitle=Alvotech与BiosanaPharma达成全球独家许可协议，共同开发Xolair®（奥马珠单抗）的拟议生物仿制药(AVT23), objectType=article, longId=295364, objectId=dce229536434, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dce229536434, replyNumber=0, likeNumber=0, createdTime=2022-02-11, rootId=0, userName=grace5701, userId=cfb42911806, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dce229536434, moduleTitle=Alvotech与BiosanaPharma达成全球独家许可协议，共同开发Xolair®（奥马珠单抗）的拟议生物仿制药(AVT23), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dce229536434)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412949, encodeId=bdda1412949e8, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, objectTitle=美国FDA批准 Cyltezo（阿达木单抗-adbm）作为第一个可与Humira互换的生物仿制药, objectType=article, longId=218852, objectId=2c2e218852d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c2e218852d4, replyNumber=0, likeNumber=36, createdTime=2021-10-20, rootId=0, userName=grace5701, userId=cfb42911806, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c2e218852d4, moduleTitle=美国FDA批准 Cyltezo（阿达木单抗-adbm）作为第一个可与Humira互换的生物仿制药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c2e218852d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412948, encodeId=6a1f1412948a3, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, objectTitle=Alvotech启动Stelara® (Ustekinumab)拟议生物仿制药AVT04的临床研究, objectType=article, longId=213917, objectId=365621391e66, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=365621391e66, replyNumber=0, likeNumber=30, createdTime=2021-07-10, rootId=0, userName=grace5701, userId=cfb42911806, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=365621391e66, moduleTitle=Alvotech启动Stelara® (Ustekinumab)拟议生物仿制药AVT04的临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=365621391e66)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412947, encodeId=73d0141294eb0, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, objectTitle=Lancet oncol：Sintilimab联合贝伐单抗生物仿制药治疗不能切除的肝癌的预后明显优于索拉非尼！, objectType=article, longId=212817, objectId=1b8121281e7b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b8121281e7b, replyNumber=0, likeNumber=38, createdTime=2021-06-18, rootId=0, userName=grace5701, userId=cfb42911806, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b8121281e7b, moduleTitle=Lancet oncol：Sintilimab联合贝伐单抗生物仿制药治疗不能切除的肝癌的预后明显优于索拉非尼！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b8121281e7b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412946, encodeId=55d11412946ae, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, objectTitle=NMPA批准BYVASDA（贝伐单抗生物仿制药）治疗复发性胶质母细胞瘤, objectType=article, longId=205139, objectId=3675205139af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3675205139af, replyNumber=0, likeNumber=42, createdTime=2021-01-02, rootId=0, userName=grace5701, userId=cfb42911806, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3675205139af, moduleTitle=NMPA批准BYVASDA（贝伐单抗生物仿制药）治疗复发性胶质母细胞瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3675205139af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412945, encodeId=0e6f141294533, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, objectTitle=Bio-Thera向欧洲药品管理局提交了Avastin生物仿制药BAT1706的营销授权申请（MAA）。, objectType=article, longId=203853, objectId=e1e7203853fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1e7203853fc, replyNumber=0, likeNumber=37, createdTime=2020-11-30, rootId=0, userName=grace5701, userId=cfb42911806, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1e7203853fc, moduleTitle=Bio-Thera向欧洲药品管理局提交了Avastin生物仿制药BAT1706的营销授权申请（MAA）。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1e7203853fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412944, encodeId=eaea14129444c, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, objectTitle=韩国三星的生物仿制药阵营或再添新成员：开始针对Denosumab生物类似物SB16进行I期临床试验, objectType=article, longId=203277, objectId=fdc22032e7e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdc22032e7e0, replyNumber=0, likeNumber=27, createdTime=2020-11-13, rootId=0, userName=grace5701, userId=cfb42911806, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdc22032e7e0, moduleTitle=韩国三星的生物仿制药阵营或再添新成员：开始针对Denosumab生物类似物SB16进行I期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fdc22032e7e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412943, encodeId=c1b91412943db, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, objectTitle=NMPA批准中国曲妥珠单抗生物仿制药, objectType=article, longId=199752, objectId=d6c5199e5254, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d6c5199e5254, replyNumber=0, likeNumber=48, createdTime=2020-08-22, rootId=0, userName=grace5701, userId=cfb42911806, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d6c5199e5254, moduleTitle=NMPA批准中国曲妥珠单抗生物仿制药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d6c5199e5254)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412942, encodeId=da8b14129427e, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, objectTitle=中国生物仿制药出海：曲妥珠单抗生物仿制药HLX02获CHMP正面评价, objectType=article, longId=195153, objectId=438319515359, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=438319515359, replyNumber=0, likeNumber=25, createdTime=2020-06-04, rootId=0, userName=grace5701, userId=cfb42911806, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=438319515359, moduleTitle=中国生物仿制药出海：曲妥珠单抗生物仿制药HLX02获CHMP正面评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=438319515359)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412941, encodeId=ecbf141294169, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, objectTitle=“药王”阿达木单抗再遇劲敌：生物仿制药AVT02取得积极结果, objectType=article, longId=194134, objectId=23531941348f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=23531941348f, replyNumber=0, likeNumber=33, createdTime=2020-05-15, rootId=0, userName=grace5701, userId=cfb42911806, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=23531941348f, moduleTitle=“药王”阿达木单抗再遇劲敌：生物仿制药AVT02取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=23531941348f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412940, encodeId=1805141294052, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, objectTitle=2020 CAG/CCC立场声明：生物仿制药治疗炎症性肠病, objectType=article, longId=188087, objectId=b4a918808ec8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4a918808ec8, replyNumber=0, likeNumber=0, createdTime=2020-02-16, rootId=0, userName=grace5701, userId=cfb42911806, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4a918808ec8, moduleTitle=2020 CAG/CCC立场声明：生物仿制药治疗炎症性肠病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b4a918808ec8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412939, encodeId=8c2c141293938, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, objectTitle=2019 立场声明：应用生物仿制药治疗炎症性肠病, objectType=article, longId=184712, objectId=e6d4184e1243, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6d4184e1243, replyNumber=0, likeNumber=24, createdTime=2019-12-14, rootId=0, userName=grace5701, userId=cfb42911806, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6d4184e1243, moduleTitle=2019 立场声明：应用生物仿制药治疗炎症性肠病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6d4184e1243)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412938, encodeId=b36014129382c, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, objectTitle=诺华的长效化重组人粒细胞集落刺激因子生物仿制药Ziextenzo获得FDA批准上市, objectType=article, longId=182505, objectId=788918250583, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=788918250583, replyNumber=0, likeNumber=47, createdTime=2019-11-08, rootId=0, userName=grace5701, userId=cfb42911806, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=788918250583, moduleTitle=诺华的长效化重组人粒细胞集落刺激因子生物仿制药Ziextenzo获得FDA批准上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=788918250583)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412937, encodeId=1b71141293e5d, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, objectTitle=AP&T：英夫利昔单抗与生物仿制药CT-P13在溃疡性结肠炎患者中的有效性和安全性比较, objectType=article, longId=177412, objectId=02521e741284, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02521e741284, replyNumber=0, likeNumber=43, createdTime=2019-08-12, rootId=0, userName=grace5701, userId=cfb42911806, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02521e741284, moduleTitle=AP&T：英夫利昔单抗与生物仿制药CT-P13在溃疡性结肠炎患者中的有效性和安全性比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02521e741284)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412936, encodeId=35c714129367e, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, objectTitle=FDA对抗体生物仿制药产品批准在2019年明显增加, objectType=article, longId=177386, objectId=08bb1e7386a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08bb1e7386a4, replyNumber=0, likeNumber=32, createdTime=2019-08-12, rootId=0, userName=grace5701, userId=cfb42911806, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08bb1e7386a4, moduleTitle=FDA对抗体生物仿制药产品批准在2019年明显增加, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=08bb1e7386a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412935, encodeId=0c4b1412935c9, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, objectTitle=Arthritis Rheumatol：培化舍珠单抗、阿巴西普和英夫利昔单抗生物仿制药治疗类风湿性关节炎的疗效比较, objectType=article, longId=175232, objectId=9d501e52321e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d501e52321e, replyNumber=0, likeNumber=37, createdTime=2019-07-13, rootId=0, userName=grace5701, userId=cfb42911806, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d501e52321e, moduleTitle=Arthritis Rheumatol：培化舍珠单抗、阿巴西普和英夫利昔单抗生物仿制药治疗类风湿性关节炎的疗效比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d501e52321e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412934, encodeId=717b14129347f, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, objectTitle=2019 ASCO：信达生物发布其贝伐单抗生物仿制药IBI305的安全性数据, objectType=article, longId=167617, objectId=95d816e61754, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=95d816e61754, replyNumber=0, likeNumber=36, createdTime=2019-06-05, rootId=0, userName=grace5701, userId=cfb42911806, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=95d816e61754, moduleTitle=2019 ASCO：信达生物发布其贝伐单抗生物仿制药IBI305的安全性数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=95d816e61754)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

生物仿制药

2020-05-29

grace5701 (审核中...)

前往app查看评论内容

#生物仿制药#

Alvotech和STADA与艾伯维解决欧洲专利纠纷，为Humira®的无柠檬酸盐、高浓度生物仿制药HUKYNDRA®(AVT02)上市铺平道路

2022-04-09

grace5701 (审核中...)

前往app查看评论内容

#生物仿制药#

FDA批准Releuko(filgrastim-ayow) ，第三种非格司亭生物仿制药

2022-03-21

grace5701 (审核中...)

前往app查看评论内容

#生物仿制药#

Alvotech就美国专利和商业秘密纠纷与AbbVie达成和解，Alvotech的拟议Humira®高浓度生物仿制药(AVT02)可在美国销售

2022-03-16

grace5701 (审核中...)

前往app查看评论内容

#生物仿制药#

Alvotech与BiosanaPharma达成全球独家许可协议，共同开发Xolair®（奥马珠单抗）的拟议生物仿制药(AVT23)

2022-02-11

grace5701 (审核中...)

前往app查看评论内容

#生物仿制药#

美国FDA批准 Cyltezo（阿达木单抗-adbm）作为第一个可与Humira互换的生物仿制药

2021-10-20

grace5701 (审核中...)

前往app查看评论内容

#生物仿制药#

Alvotech启动Stelara® (Ustekinumab)拟议生物仿制药AVT04的临床研究

2021-07-10

grace5701 (审核中...)

前往app查看评论内容

#生物仿制药#

Lancet oncol：Sintilimab联合贝伐单抗生物仿制药治疗不能切除的肝癌的预后明显优于索拉非尼！

2021-06-18

grace5701 (审核中...)

前往app查看评论内容

#生物仿制药#

NMPA批准BYVASDA（贝伐单抗生物仿制药）治疗复发性胶质母细胞瘤

2021-01-02

grace5701 (审核中...)

前往app查看评论内容

#生物仿制药#

Bio-Thera向欧洲药品管理局提交了Avastin生物仿制药BAT1706的营销授权申请（MAA）。

2020-11-30

grace5701 (审核中...)

前往app查看评论内容

#生物仿制药#

韩国三星的生物仿制药阵营或再添新成员：开始针对Denosumab生物类似物SB16进行I期临床试验

2020-11-13

grace5701 (审核中...)

前往app查看评论内容

#生物仿制药#

NMPA批准中国曲妥珠单抗生物仿制药

2020-08-22

grace5701 (审核中...)

前往app查看评论内容

#生物仿制药#

中国生物仿制药出海：曲妥珠单抗生物仿制药HLX02获CHMP正面评价

2020-06-04

grace5701 (审核中...)

前往app查看评论内容

#生物仿制药#

“药王”阿达木单抗再遇劲敌：生物仿制药AVT02取得积极结果

2020-05-15

grace5701 (审核中...)

前往app查看评论内容

#生物仿制药#

2020 CAG/CCC立场声明：生物仿制药治疗炎症性肠病

2020-02-16

grace5701 (审核中...)

前往app查看评论内容

#生物仿制药#

2019 立场声明：应用生物仿制药治疗炎症性肠病

2019-12-14

grace5701 (审核中...)

前往app查看评论内容

#生物仿制药#

诺华的长效化重组人粒细胞集落刺激因子生物仿制药Ziextenzo获得FDA批准上市

2019-11-08

grace5701 (审核中...)

前往app查看评论内容

#生物仿制药#

AP&T：英夫利昔单抗与生物仿制药CT-P13在溃疡性结肠炎患者中的有效性和安全性比较

2019-08-12

grace5701 (审核中...)

前往app查看评论内容

#生物仿制药#

FDA对抗体生物仿制药产品批准在2019年明显增加

2019-08-12

grace5701 (审核中...)

前往app查看评论内容

#生物仿制药#

Arthritis Rheumatol：培化舍珠单抗、阿巴西普和英夫利昔单抗生物仿制药治疗类风湿性关节炎的疗效比较

2019-07-13

grace5701 (审核中...)

前往app查看评论内容

#生物仿制药#

2019 ASCO：信达生物发布其贝伐单抗生物仿制药IBI305的安全性数据

2019-06-05

科室
- - 订阅+
  - 更多科室
工具
服务